Hematologic Malignancy
Megakaryocytic Neoplasm
CI-CAN-00001205Explore in graph →
Hematologic26 active trials1 approved drugs2 evidence items
- NCIt
- C7066
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001205Explore in graph →
Clinical trials
168 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (25)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01134120 | A Study in Myeloproliferative Disorders | completed | Phase 1 | 80 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01801046 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | terminated | Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT01970930 |
| Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients |
| completed |
| — |
| 131 |
| Icahn School of Medicine at Mount SinaiOTHER |
| 1 |
| Jan 19, 2018 |
| clinicaltrials |
| NCT00445744 | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | completed | N/A | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01831232 | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | N/A | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00666289 | Familial Myeloproliferative Disorders | completed | — | 17 | Icahn School of Medicine at Mount SinaiOTHER | 2 | Sep 5, 2017 | clinicaltrials |
| NCT00462605 | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2017 | clinicaltrials |
| NCT00433862 | Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders | completed | — | 8 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01342887 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00673153 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | terminated | Phase 2 | 31 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01820624 | Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 12 | Paolo Caimi, MDOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT01520220 | Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms | completed | Phase 1 | 100 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 12, 2017 | clinicaltrials |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | terminated | Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01870596 | Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2016 | clinicaltrials |
| NCT01076569 | Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia | completed | — | 250 | Children's Oncology GroupNETWORK | 1 | May 19, 2016 | clinicaltrials |
| NCT01642069 | Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia | completed | — | 100 | Children's Oncology GroupNETWORK | 1 | May 18, 2016 | clinicaltrials |
| NCT01146210 | Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | — | 20 | Children's Oncology GroupNETWORK | 1 | May 17, 2016 | clinicaltrials |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT02663648 | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | withdrawn | — | 0 | Shandong UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01243073 | Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera(ET/PV) | completed | Phase 2 | 20 | Geron CorporationINDUSTRY | 3 | Jan 26, 2016 | clinicaltrials |
| NCT00586651 | Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis | completed | Phase 2 | 39 | CephalonINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT01127009 | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00407966 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2015 | clinicaltrials |
| NCT02076815 | Anagrelide Retard in Essential Thrombocythemia(TEAM-ET) | completed | Phase 3 | 106 | AOP Orphan Pharmaceuticals AGINDUSTRY | 5 | Jul 29, 2015 | clinicaltrials |
| NCT00634244 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2015 | clinicaltrials |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy | terminated | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00217646 | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00383474 | Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01361464 | Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2015 | clinicaltrials |
| NCT00381550 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2015 | clinicaltrials |
| NCT00668421 | CEP-701 (Lestaurtinib) in Myelofibrosis | unknown | Phase 1 / Phase 2 | 60 | Ronald HoffmanOTHER | 1 | Nov 26, 2014 | clinicaltrials |
| NCT00602771 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00742625 | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00096122 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00227591 | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00305773 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 19, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00039416 | Imatinib Mesylate in Treating Patients With Myelofibrosis | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00098423 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301938 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00470197 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00003190 | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 640 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00006363 | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | completed | Phase 3 | 720 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00047190 | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | terminated | Phase 1 | 88 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Apr 17, 2018source: clinicaltrials